LEADER trial eligibility and preventable cardiovascular events in US adults with diabetes: the National Health and Nutrition Examination Surveys 2007-2016

Abstract

Liraglutide may prevent many fatal and non-fatal CVD events if provided to US adults meeting LEADER eligibility criteria. More efforts are needed to educate healthcare providers on the CVD benefits of newer diabetes therapies.

Citation
Fan W, Tong C, Wong ND. Cardiovasc Drugs Ther 2020; epub ahead of press.